Article
Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.
The New England journal of medicine - 27 Aug 2020
Drilon Alexander, Oxnard Geoffrey R, Tan Daniel S W, Loong Herbert H F, Johnson Melissa, Gainor Justin, McCoach Caroline E, Gautschi Oliver, Besse Benjamin, Cho Byoung C, Peled Nir, Weiss Jared, Kim Yu-Jung, Ohe Yuichiro, Nishio Makoto, Park Keunchil, Patel Jyoti, Seto Takashi, Sakamoto Tomohiro, Rosen Ezra, Shah Manisha H, Barlesi Fabrice, Cassier Philippe A, Bazhenova Lyudmila, De Braud Filippo, Garralda Elena, Velcheti Vamsidhar, Satouchi Miyako, Ohashi Kadoaki, Pennell Nathan A, Reckamp Karen L, Dy Grace K, Wolf Jürgen, Solomon Benjamin, Falchook Gerald, Ebata Kevin, Nguyen Michele, Nair Binoj, Zhu Edward Y, Yang Luxi, Huang Xin, Olek Elizabeth, Rothenberg S Michael, Goto Koichi, Subbiah Vivek
Abstract excerpt
BACKGROUND: RET fusions are oncogenic drivers in 1 to 2% of non-small-cell lung cancers (NSCLCs). In patients with RET fusion-positive NSCLC, the efficacy and safety of selective RET inhibition are unknown. METHODS: We enrolled patients with advanced RET fusion-positive NSCLC who had previously received platinum-based chemotherapy and those who were previously untreated separately in a phase 1-2 trial of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.